Letters to the Editor
Early Access
Treatment of scleromyxedema Arndt-Gottron with a novel intravenous immunoglobulin preparation
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 14 April 2026
137
Views
83
Downloads
Authors
Dear Editor,
Scleromyxedema is known as a rare, severe mucinosis with characteristic waxy skin papules along with sclerodermiform induration of the skin and rare systemic manifestations. Monoclonal gammopathy of undetermined significance (MGUS; mostly monoclonal immunoglobulin G [IgG] type lambda) can be detected in up to 90% of patients. [...]
Downloads
Download data is not yet available.
Citations
1. Hoffmann JHO, Enk AH. Scleromyxedema. J Dtsch Dermatol Ges 2020;18:1449-67.
2. Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001;44:273-81.
3. Mecoli CA, Talbot CC, Fava A, et al. Clinical and Molecular Phenotyping in Scleromyxedema Pretreatment and Posttreatment With Intravenous Immunoglobulin. Arthritis Care Res (Hoboken) 2020;72:761-7.
4. Harper RA, Rispler J. Lichen Myxedematosus Serum Stimulates Human Skin Fibroblast Proliferation. Science 1978;199:545-7.
5. Ferrarini M, Helfrich DJ, Walker ER, et al. Scleromyxedema serum increases proliferation but not the glycosaminoglycan synthesis of dermal fibroblasts. J Rheumatol 1989;16:837-41.
6. Yaron M, Yaron I, Yust I, Brenner S. Lichen myxedematosus (scleromyxedema) serum stimulates hyaluronic acid and prostaglandin E production by human fibroblasts. J Rheumatol 1985;12:171-5.
7. Karim A, Lawlor F, Black MM. Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin. Clin Exp Dermatol 2004;29:317-8.
8. Feldmeyer L, Benden C, Haile S, et al. Not All Intravenous Immunoglobulin Preparations are Equally Well Tolerated. Acta Derm Venereol 2010;90:494-7.
9. Chérin P, Cabane J. Relevant Criteria for Selecting an Intravenous Immunoglobulin Preparation for Clinical Use. BioDrugs 2010;24:211-23.
10. Ameratunga R, Sinclair J, Kolbe J. Increased risk of adverse events when changing intravenous immunoglobulin preparations. Clin Exp Immunol 2004;136:111-3.
How to Cite
1.
Negele N, Winkler JK, Enk AH. Treatment of scleromyxedema Arndt-Gottron with a novel intravenous immunoglobulin preparation. Dermatol Reports [Internet]. 2026 Apr. 14 [cited 2026 Jun. 3];. Available from: https://journals.pagepress.net/dr/article/view/10557
Copyright (c) 2026 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
